Management of Complex Regional Pain Syndrome (CRPS) with LDN (Low Dose Naltrexone)

LDN for Complex Regional Pain Syndrome

Pradeep Chopra, MD, MHCM

Abstract

Complex Regional Pain Syndrome (CRPS) is a debilitating chronic pain condition characterized by severe pain, autonomic dysregulation, and sensory abnormalities. Traditional treatments often yield suboptimal results, prompting exploration of alternative therapies. This report presents the case of a 24-year-old female diagnosed with CRPS who experienced significant symptomatic improvement following treatment with low-dose naltrexone (LDN).

Introduction

CRPS is a neuropathic pain disorder that typically follows trauma, surgery, or other inciting events. Current treatment options include physical therapy, pharmacotherapy, and interventional procedures, but many patients continue to experience significant morbidity. Emerging evidence suggests that LDN, an opioid antagonist with anti-inflammatory and immunomodulatory properties, may offer a novel therapeutic approach.^{[1] [2]}

Case Presentation

A 24-year-old previously healthy female presented with severe burning pain, hyperalgesia, and allodynia in her right lower extremity following a minor ankle sprain. Over several weeks, her symptoms progressed to include swelling, temperature dysregulation, and significant functional impairment. Clinical examination and diagnostic testing confirmed a diagnosis of CRPS Type I based on the Budapest Criteria. According to these criteria, CRPS is diagnosed when a patient exhibits continuing pain disproportionate to any inciting event and at least one symptom in three of the four following categories: sensory (hyperalgesia, allodynia), vasomotor (temperature asymmetry, skin color changes), sudomotor/edema (edema, sweating asymmetry), and motor/trophic (decreased range of motion, tremors, dystonia, changes in hair/nail growth). Additionally, at least one sign in two or more of these categories must be observed on examination. Initial management included nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentinoids, and physical therapy, with minimal symptom relief.

Symptoms and Signs of CRPS

CRPS is characterized by a constellation of sensory, autonomic, motor, and trophic changes that typically affect an extremity. The primary symptom is intense, disproportionate pain, often described as burning, stabbing, or throbbing. This pain is accompanied by hyperalgesia (increased sensitivity to pain) and allodynia (pain elicited by non-painful stimuli such as light touch). Autonomic dysfunction manifests as abnormal skin color changes, temperature asymmetry, and excessive sweating in the affected limb. Edema and swelling may also be present. Motor disturbances include weakness, tremors, dystonia, and impaired coordination. Trophic changes, including alterations in hair growth, nail texture, and skin atrophy, further contribute to the clinical picture. These symptoms often progress in stages, with early intervention being crucial for a better prognosis.^[3]

Due to inadequate response to conventional therapy, the patient was started on LDN at a dose of 4.5 mg once a day. Within six weeks of initiating LDN, the patient reported a marked reduction in pain intensity, improved mobility, and diminished sensory abnormalities. By three months, her functional status had significantly improved, and pain levels had decreased by more than 50%. No adverse effects were reported.

Central Sensitization and CRPS

CRPS is strongly linked to Central Sensitization, a process in which the central nervous system becomes hyperresponsive to stimuli following an initial injury. This heightened response is driven by increased excitability of neurons in the dorsal horn, persistent microglial activation, and altered pain processing pathways. Central sensitization leads to exaggerated pain perception, hyperalgesia, and allodynia, contributing to the chronic and often refractory nature of CRPS.^[4] Given its role in modulating neuroinflammation and glial cell activation, LDN has been proposed as a promising therapeutic option for conditions characterized by central sensitization, including CRPS^[5].

Glial Cell Activation and Pain Modulation

Glial cells, including microglia and astrocytes, play a crucial role in the development and maintenance of central sensitization. Following an injury or prolonged pain stimulus, microglia become activated and release pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These inflammatory mediators enhance synaptic transmission, increase neuronal excitability, and decrease endogenous pain inhibition, leading to sustained pain hypersensitivity. Additionally, astrocytes contribute to neuroinflammation by releasing glutamate and other excitatory neurotransmitters that exacerbate pain signaling. By modulating microglial activation and reducing neuroinflammatory cascades, LDN may help restore normal pain processing and mitigate the symptoms of CRPS.^[6]

Toll-Like Receptors and Pain Modulation

LDN has been shown to modulate the activity of toll-like receptors (TLRs), particularly TLR4, which is predominantly expressed in microglia. TLR4 activation plays a key role in the propagation of neuroinflammation and chronic pain by triggering the release of pro-inflammatory cytokines and excitatory neurotransmitters. By acting as a partial antagonist to TLR4, LDN reduces the inflammatory signaling that contributes to central sensitization and persistent pain. This effect helps to decrease neuronal excitability and ultimately leads to improved pain modulation, making LDN a promising therapeutic option for CRPS and other chronic pain disorders.^[7]

Opioid Growth Factor and Pain Modulation

LDN has also been shown to influence the opioid growth factor (OGF) pathway, which plays a critical role in pain modulation and immune regulation. OGF, also known as met-enkephalin, binds to the opioid growth factor receptor (OGFr) and regulates cell proliferation and immune function. LDN temporarily blocks the OGF-OGFr interaction, leading to a compensatory increase in endogenous OGF production and receptor sensitivity. This enhanced OGF activity helps to modulate pain perception, reduce neuroinflammation, and promote tissue repair, further contributing to LDN's therapeutic effects in CRPS and other chronic pain conditions.^[8]

Discussion

LDN is increasingly recognized for its potential benefits in chronic pain conditions, likely mediated through its effects on microglial modulation and opioid receptor antagonism.^[9] LDN exerts its analgesic effects through several mechanisms. First, it temporarily blocks opioid receptors, leading to a compensatory upregulation of endogenous opioid production, enhancing natural pain relief. Additionally, LDN modulates microglial activity, reducing the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. By dampening neuroinflammation, LDN helps decrease neuronal excitability and interrupt the cycle of central sensitization. Furthermore, LDN has been shown to promote neuroprotection and enhance mitochondrial function, potentially contributing to its efficacy in CRPS and other chronic pain syndromes.

Conclusion

This case highlights the potential efficacy and safety of LDN in managing CRPS. Given its favorable safety profile and promising outcomes, LDN may represent an important addition to the therapeutic armamentarium for CRPS. Future clinical trials are warranted to establish standardized treatment protocols.

‌

‍

^[1] Younger, Jarred, et al., 2014. “The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain.” Clinical Rheumatology 33 (4): 451–59. https://doi.org/10.1007/s10067-014-2517-2.

^[1] Chopra, Pradeep, and Mark S. Cooper. 2013. “Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN).” Journal of Neuroimmune Pharmacology 8 (3): 470–76. https://doi.org/10.1007/s11481-013-9451-y

^[1] Harden, R. Norman, et al., 2007. “Proposed New Diagnostic Criteria for Complex Regional Pain Syndrome.” Pain Medicine 8 (4): 326–31. https://doi.org/10.1111/j.1526-4637.2006.00169.x.

^[1] Latremoliere, Alban, and Clifford J. Woolf. 2009. “Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity.” The Journal of Pain 10 (9): 895–926. https://doi.org/10.1016/j.jpain.2009.06.012.

^[1] Rupp, Adam et al., 2023. “Low Dose Naltrexone’s Utility for Non-Cancer Centralized Pain Conditions - a Scoping Review.” Pain Medicine, June. https://doi.org/10.1093/pm/pnad074.

‌

^[1] Watkins, Linda R., et al., 2001. “Glial Activation: A Driving Force for Pathological Pain.” Trends in Neurosciences 24 (8): 450–55. https://doi.org/10.1016/s0166-2236(00)01854-3.

‌‌

^[1] Bruno et al., 2018. “Targeting Toll-like Receptor-4 (TLR4)—an Emerging Therapeutic Target for Persistent Pain States.” Pain 159 (10): 1908–15. https://doi.org/10.1097/j.pain.0000000000001306.

‌

^[1] Zagon, Ian S, and Patricia J McLaughlin. 2018. “Intermittent Blockade of OGFr and Treatment of Autoimmune Disorders.” Experimental Biology and Medicine 243 (17-18): 1323–30. https://doi.org/10.1177/1535370218817746.

‍